3 01, 2023

Accelerating Clinical Trials in EU: 2022-2026 workplan

By |2023-01-04T14:28:54+00:00January 3rd, 2023|General News|

The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the 2022-2026 workplan of the initiative Accelerating Clinical Trials in the EU (ACT EU). ACT EU, launched in January 2022, seeks to transform how clinical trials are initiated, designed and run. The aim is to further develop the EU as a focal

19 09, 2022

Reminder: 4 days to BREXIT Event!

By |2024-01-02T10:40:40+00:00September 19th, 2022|Featured, General News|

Our CEO Ann McGee will be speaking at the Pharma and Brexit Conference - hosted by PDA Ireland and PDA United Kingdom. The event will focus on the impact, challenges and solutions for the pharmaceutical industry. Register now on Eventbrite: https://lnkd.in/eVxTutkC Date - September 23rd, 2022 Venue - Crowne Plaza Hotel, Dublin Airport Time - 8:00 a.m. -

14 09, 2022

We Welcome our New CEO Pierre-Henri Baviera

By |2024-01-02T10:42:25+00:00September 14th, 2022|Featured, General News|

We are very excited to announce the appointment of Pierre-HenriBaviera as the new CEO for Mias Pharma Limited.  As an experienced CEO, Pierre brings significant senior international leadership capabilities in Professional Services and Technology companies. He will be focused on the next phase of growth for MIAS's people and customers in line with our

17 08, 2022

Major Pharma Conferences and Events to Attend in 2024

By |2024-05-17T16:55:40+01:00August 17th, 2022|Events, General News|

We've comprised a list of some of the biggest pharma events and conferences taking place in Europe and USA for pharma businesses willing to attend and stay up to date with the latest advancements in the industry or connect with possible partners. MIAS Pharma will be attending some of the events from this list

27 07, 2022

Extension of the comment period by FDA

By |2022-10-18T16:03:00+01:00July 27th, 2022|Featured, General News, Industry News|

FDA Proposed Rule "National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers" In February 2022, the FDA has announced the availability of the proposed rule "National Standards for the Licensure of Wholesale Drug Distributors (WDDs) and Third-Party Logistics Providers (3PLs)". The proposed rule sets national licensing standards for both federal and

15 12, 2021

Merry Christmas and Happy New Year

By |2024-01-09T12:06:28+00:00December 15th, 2021|Featured, General News|

MIAS has continued exceptional growth and development over 2021. We'd like to thank our Team, Customers and Suppliers for contributing to the continued success of MIAS. We would like to wish you all a very Merry Christmas and we look forward to what will come in 2022. Our offices will close on Friday 24th

18 11, 2021

Welcome to the Team

By |2024-01-02T10:42:04+00:00November 18th, 2021|Featured, General News|

We would like to welcome Ciara Kearney, Lisa Evans, Sherry A Calimlim and Olivia McEvoy to the MIAS Pharma Team. They are a very welcome addition to the team and we look forward to a long and fruitful career with MIAS.

12 10, 2020

MHRA (GxP) Inspections during COVID19

By |2024-02-12T11:23:42+00:00October 12th, 2020|General News|

The COVID19 pandemic presents an unprecedented challenge to healthcare, the pharmaceutical industry’s supply chain and personnel movement. MHRA understands the impact of its work on industry, NHS and patients. This is not just in terms of our regulatory support to bring new technologies and products quickly and safely to market, but also the personnel

5 10, 2020

Regulations for Pharmaceuticals Post Brexit

By |2021-10-13T14:30:17+01:00October 5th, 2020|General News|

The European Commission has published a Communication to prepare for the end of the transition period. The document is appropriately entitled "Getting ready for changes - Communication on readiness at the end of the transition period between the European Union and the United Kingdom". Far-reaching changes and consequences are therefore to be expected after 1

30 09, 2020

Complying with new GDP requirements

By |2021-10-13T14:27:04+01:00September 30th, 2020|General News|

In an ever changing and complex industry the role of the Responsible Person has developed and grown over the past 10 years as the focus of regulatory bodies have placed a higher level of scrutiny on how GDP principals are implemented and applied for Wholesale Distributors. Initially the main areas of compliance for

Go to Top